Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
Delayed Nasdaq  -  03:58 2022-09-28 pm EDT
63.01 USD   +2.02%
09/16Transcript : Apellis Pharmaceuticals, Inc. Presents at BofA Securities Global Healthcare Conference 2022, Sep-16-2022 08:55 AM
CI
09/12Insider Sell: Apellis Pharmaceuticals
MT
09/12Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q2 Revenue $16.3M

08/08/2022 | 04:08pm EDT


© MT Newswires 2022
All news about APELLIS PHARMACEUTICALS, INC.
09/16Transcript : Apellis Pharmaceuticals, Inc. Presents at BofA Securities Global..
CI
09/12Insider Sell: Apellis Pharmaceuticals
MT
09/12Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global H..
GL
09/12Wedbush Raises Price Target on Apellis Pharmaceuticals to $67 From $55, Sees Increased ..
MT
09/08Insider Sell: Apellis Pharmaceuticals
MT
09/08Stifel Nicolaus Adjusts Price Target on Apellis Pharmaceuticals to $65 From $60, Keeps ..
MT
09/07Insider Sell: Apellis Pharmaceuticals
MT
09/07Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
GL
09/07Transcript : Apellis Pharmaceuticals, Inc. Presents at Citi's 17th Annual Bio..
CI
09/07B. Riley Downgrades IVERIC bio to Sell from Neutral After 'Disappointing' Data Which Re..
MT
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 79,1 M - -
Net income 2022 -627 M - -
Net cash 2022 400 M - -
P/E ratio 2022 -10,4x
Yield 2022 -
Capitalization 6 785 M 6 785 M -
EV / Sales 2022 80,7x
EV / Sales 2023 24,8x
Nbr of Employees 476
Free-Float 84,5%
Chart APELLIS PHARMACEUTICALS, INC.
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 61,76 $
Average target price 77,82 $
Spread / Average Target 26,0%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Federico Grossi Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
APELLIS PHARMACEUTICALS, INC.30.63%6 785
CSL LIMITED-2.09%88 434
SAMSUNG BIOLOGICS CO.,LTD.-15.06%37 595
BIOGEN INC.-17.56%28 702
WUXI BIOLOGICS (CAYMAN) INC.-47.16%26 568
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-32.25%19 595